Tarsheen Sethi

Tarsheen Sethi, MD, MSCI, is an Assistant Professor of Medicine (Hematology) at Yale School of Medicine and Director of the Yale Affiliated Hospital Program for Hematology Section. She specializes in treating Hodgkin and non-Hodgkin lymphomas, with a focus on translational research and clinical trials targeting novel therapies. Her work emphasizes improving patient outcomes through immunotherapy and tumor biology insights.

Education:

• MD: Maulana Azad Medical College, New Delhi (2005)
• MSc in Clinical Investigation: Vanderbilt University (2018)
• Fellowship: Hematology-Oncology, Vanderbilt University Medical Center (2018)

Research Interests: Dr. Sethi's research focuses on lymphoma treatment strategies, including CAR-T cell therapy, molecular determinants of response, and clinical outcomes in rare lymphomas. She investigates applications of tumor immunology and immunotherapy for hematologic malignancies.

Publications: Her work spans over 50 peer-reviewed articles, emphasizing clinical trials, treatment efficacy, and biomarker identification. Key themes include GvHD prophylaxis in transplantation, CAR-T therapy outcomes, and genetic predictors in cutaneous lymphomas.

Awards:

• PhRMA Foundation Award in Translational Medicine (2013)
• American Society of Hematology Abstract Achievement Award (2016)
• Top Internal Medicine in-service exam scores (University of Louisville, 2012-2013)

Grants & Clinical Trials: Leads and participates in trials for novel lymphoma therapies, including studies on soquelitinib, talquetamab, and mogamulizumab. Engaged in Yale Cancer Center’s Protocol Review Committee and New England Hematologic Malignancies Symposium planning.

Labs & Teams: Collaborates with the Leukemia & Lymphoma Program and Yale Cancer Center. Active in multidisciplinary teams advancing precision oncology and immunotherapy.